Wall Street analysts forecast that Calyxt Inc (NASDAQ:CLXT) will announce earnings per share of ($0.32) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Calyxt’s earnings. Calyxt posted earnings per share of ($0.26) during the same quarter last year, which indicates a negative year over year growth rate of 23.1%. The business is expected to announce its next quarterly earnings results on Monday, March 9th.
On average, analysts expect that Calyxt will report full year earnings of ($1.11) per share for the current financial year, with EPS estimates ranging from ($1.13) to ($1.08). For the next fiscal year, analysts expect that the company will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.05) to ($1.01). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Calyxt.
Calyxt (NASDAQ:CLXT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.01). The business had revenue of $2.97 million during the quarter. Calyxt had a negative net margin of 5,509.93% and a negative return on equity of 36.21%.
A number of brokerages have recently issued reports on CLXT. BMO Capital Markets dropped their price objective on Calyxt to $15.00 and set an “outperform” rating on the stock in a research note on Friday. National Securities reissued a “buy” rating and issued a $28.00 price objective (down from $35.00) on shares of Calyxt in a research note on Thursday, August 8th. BidaskClub raised Calyxt from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 12th. Finally, Zacks Investment Research downgraded Calyxt from a “buy” rating to a “hold” rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Calyxt has a consensus rating of “Hold” and an average price target of $18.25.
A number of institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System increased its position in Calyxt by 7.8% in the 3rd quarter. California Public Employees Retirement System now owns 94,401 shares of the company’s stock valued at $532,000 after buying an additional 6,801 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Calyxt by 56.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 21,848 shares of the company’s stock valued at $273,000 after buying an additional 7,887 shares in the last quarter. Wells Fargo & Company MN increased its position in Calyxt by 52.3% in the 2nd quarter. Wells Fargo & Company MN now owns 24,679 shares of the company’s stock valued at $309,000 after buying an additional 8,475 shares in the last quarter. Essex Investment Management Co. LLC increased its position in Calyxt by 91.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 22,436 shares of the company’s stock valued at $127,000 after buying an additional 10,716 shares in the last quarter. Finally, River & Mercantile Asset Management LLP bought a new stake in Calyxt in the 2nd quarter valued at about $146,000. 28.19% of the stock is owned by institutional investors and hedge funds.
NASDAQ:CLXT traded down $0.28 during mid-day trading on Friday, hitting $4.05. 414,300 shares of the stock were exchanged, compared to its average volume of 67,574. The stock has a market capitalization of $158.09 million, a price-to-earnings ratio of -4.45 and a beta of 2.41. The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.94 and a current ratio of 15.96. The firm’s 50-day simple moving average is $5.10 and its 200 day simple moving average is $9.60. Calyxt has a fifty-two week low of $3.83 and a fifty-two week high of $19.30.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.